-
Something wrong with this record ?
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
P. Novodvorský, M. Haluzík
Language English Country Great Britain
Document type Journal Article
- MeSH
- Diabetes Mellitus, Type 2 * drug therapy MeSH
- Drug Combinations MeSH
- Glycated Hemoglobin MeSH
- Hypoglycemia * chemically induced MeSH
- Hypoglycemic Agents adverse effects MeSH
- Insulin Glargine therapeutic use MeSH
- Blood Glucose MeSH
- Humans MeSH
- Glucagon-Like Peptide-1 Receptor agonists MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
INTRODUCTION: Recent development of novel antidiabetic drugs with proven cardiovascular (CV) and renal benefit and positive effect on body weight enable to take a more complex approach toward the management of type 2 diabetes mellitus (T2DM). Fixed-ratio combinations of insulin-GLP-1 receptor agonist (FRC) utilize complementary mechanisms of action of their individual components and address multiple pathologies linked with T2DM at the same time. AREAS COVERED: There are currently three FRCs on the market: iGlarLixi (glargine and lixisenatide in 2 different formulations) and IDegLira (degludec and liraglutide). We provide an up-to-date review on the rationale for the use of FRCs and their current position in the management of T2DM. We discuss the available evidence from randomized controlled trials, post hoc analyses, indirect comparative studies and real-world data on their effect on glycemic control, risk of hypoglycemia, body weight, CV safety, and their safety profile. EXPERT OPINION: FRCs represent an efficacious option for treatment intensification from basal insulin or even the first insulin-based therapy in T2DM. Their excellent glucose-lowering efficacy is complemented with lower risk of hypoglycemia in comparison to basal insulin, neutral effect on body weight and the lower risk of gastrointestinal adverse effects in comparison to GLP-1 receptor agonists.
1st Faculty of Medicine Charles University Prague Czech Republic
Department of Oncology and Metabolism University of Sheffield Sheffield UK
Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010855
- 003
- CZ-PrNML
- 005
- 20220815125628.0
- 007
- ta
- 008
- 220425s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14740338.2021.1978974 $2 doi
- 035 __
- $a (PubMed)34641742
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Novodvorský, Peter $u Diabetes Centre, Institute for Clinical and Experimental Medicine (Ikem), Prague, Czech Republic $u Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK $u MUDr. Korecová Metabolické Centrum, Trenčín, Slovakia $1 https://orcid.org/0000000232927586 $7 xx0275745
- 245 13
- $a An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus / $c P. Novodvorský, M. Haluzík
- 520 9_
- $a INTRODUCTION: Recent development of novel antidiabetic drugs with proven cardiovascular (CV) and renal benefit and positive effect on body weight enable to take a more complex approach toward the management of type 2 diabetes mellitus (T2DM). Fixed-ratio combinations of insulin-GLP-1 receptor agonist (FRC) utilize complementary mechanisms of action of their individual components and address multiple pathologies linked with T2DM at the same time. AREAS COVERED: There are currently three FRCs on the market: iGlarLixi (glargine and lixisenatide in 2 different formulations) and IDegLira (degludec and liraglutide). We provide an up-to-date review on the rationale for the use of FRCs and their current position in the management of T2DM. We discuss the available evidence from randomized controlled trials, post hoc analyses, indirect comparative studies and real-world data on their effect on glycemic control, risk of hypoglycemia, body weight, CV safety, and their safety profile. EXPERT OPINION: FRCs represent an efficacious option for treatment intensification from basal insulin or even the first insulin-based therapy in T2DM. Their excellent glucose-lowering efficacy is complemented with lower risk of hypoglycemia in comparison to basal insulin, neutral effect on body weight and the lower risk of gastrointestinal adverse effects in comparison to GLP-1 receptor agonists.
- 650 _2
- $a krevní glukóza $7 D001786
- 650 12
- $a diabetes mellitus 2. typu $x farmakoterapie $7 D003924
- 650 _2
- $a fixní kombinace léků $7 D004338
- 650 _2
- $a receptor pro glukagonu podobný peptid 1 $x agonisté $7 D000067757
- 650 _2
- $a glykovaný hemoglobin $7 D006442
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a hypoglykemie $x chemicky indukované $7 D007003
- 650 _2
- $a hypoglykemika $x škodlivé účinky $7 D007004
- 650 _2
- $a inzulin glargin $x terapeutické užití $7 D000069036
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Haluzík, Martin $u Diabetes Centre, Institute for Clinical and Experimental Medicine (Ikem), Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00186210 $t Expert opinion on drug safety $x 1744-764X $g Roč. 21, č. 3 (2022), s. 349-361
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34641742 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220815125627 $b ABA008
- 999 __
- $a ok $b bmc $g 1788796 $s 1162053
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 21 $c 3 $d 349-361 $e 20211013 $i 1744-764X $m Expert opinion on drug safety $n Expert Opin Drug Saf $x MED00186210
- LZP __
- $a Pubmed-20220425
